Floatz logo

Ganciclovir

Cytomegalovirus Retinitis

Small moleculePhase 4 / ApprovedDormant
A
82/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
73/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Cytomegalovirus Retinitis cohort.

Asset / SponsorPhaseRating
Vistide
National Center for Research Resources (NCRR)
Phase 4BBB

Same molecule, other indications

Ganciclovir is also rated in:

HIV infectious diseaseDormant
BBB
Indicative · Phase 4
76 / 100
View asset →
cytomegalovirus infectionActive
BB
Indicative · Phase 3
67 / 100
View asset →
lymphomaDormant
B
Indicative · Phase 2
61 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →